Novo Nordisk Cuts Wegovy to $149 Monthly Ahead of Generics

New Patient Assistance Pricing Structure

The company's patient assistance program now offers Wegovy 1.5mg at $149 per month and maintains the same price for the 4mg dose through August 2026. After that date, the 4mg formulation will increase to $199 monthly, according to program terms published on the manufacturer's website.

This pricing represents a significant reduction from standard retail costs, where patients typically pay between $300-400 monthly for branded semaglutide medications across Canadian pharmacies including Shoppers Drug Mart, Costco, and Walmart.

Timing Coincides with Generic Competition

The promotional pricing launch comes as Health Canada reviews nine generic semaglutide applications, with approvals expected in mid-2026. Generic manufacturers including Sandoz, Apotex, Teva, and Aspen Pharmacare are targeting Canadian market entry following the January 2026 patent expiration for Ozempic.

Aspen Pharmacare has specifically announced plans to launch generic semaglutide in Canada by the third quarter of 2026, positioning the country as a reference market for emerging regions. Dr. Reddy's Laboratories and other manufacturers have also filed applications under Health Canada's 180-day review timeline.

Market Access Strategy

Industry analysts suggest the timing of Novo Nordisk's pricing strategy reflects preparation for substantial market share erosion once generic alternatives become available. Generic semaglutide products are expected to launch at approximately 35% of current brand prices, potentially bringing monthly costs below $100.

The promotional pricing applies only to "eligible patients" under full program terms, though specific eligibility criteria were not detailed in the company's public materials. Patients can check coverage options through our insurance coverage checker to determine applicable pricing.

Canadian Market Dynamics

Canadian semaglutide sales reached $3.5 billion in 2025 according to IQVIA data, with approximately 3 million Canadians currently using GLP-1 medications. The substantial market size has attracted multiple generic manufacturers seeking to capture market share once exclusivity periods expire.

Novo Nordisk has also introduced new brand names Plosbrio and Poviztra for semaglutide products in Canada, potentially as part of a broader strategy to maintain market position against generic competition. These brand extensions received Health Canada approval earlier this year.

Regulatory Status Updates

Health Canada's generic submissions tracker shows active reviews for semaglutide applications from multiple manufacturers. The regulatory agency has committed to 180-day review timelines for generic applications, which industry observers note is faster than many global regulatory authorities.

Patients awaiting generic options can monitor approval status through our generic semaglutide tracker, which provides updates on Health Canada review progress and expected launch dates.

Additional information about GLP-1 medication access and pricing is available in our FAQ section.